Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy.
暂无分享,去创建一个
J. Björk | E. Erfurth | V. Popović | B. Ekman | H. Holmer | C. Nordstöm | A. Siversson
[1] T. Reinehr,et al. Reduced Sympathetic Metabolites in Urine of Obese Patients With Craniopharyngioma , 2006, Pediatric Research.
[2] G. Walldius,et al. The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence , 2006, Journal of internal medicine.
[3] J. Shaw,et al. Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[4] A. Emser,et al. Melatonin Treatment in Obese Patients with Childhood Craniopharyngioma and Increased Daytime Sleepiness , 2006, Cancer Causes & Control.
[5] B. M. King,et al. The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight , 2006, Physiology & Behavior.
[6] M. Kołtowska-Häggström,et al. Estrogen replacement in women of fertile years with hypopituitarism. , 2005, The Journal of clinical endocrinology and metabolism.
[7] Paul Zimmet,et al. The metabolic syndrome—a new worldwide definition , 2005, The Lancet.
[8] M. Kołtowska-Häggström,et al. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). , 2005, The Journal of clinical endocrinology and metabolism.
[9] B E Ainsworth,et al. How many days of pedometer monitoring predict weekly physical activity in adults? , 2005, Preventive medicine.
[10] J. Romijn,et al. High prevalence of long‐term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma , 2005, Clinical endocrinology.
[11] P. Clayton,et al. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. , 2005, European journal of endocrinology.
[12] M. Kołtowska-Häggström,et al. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database). , 2004, The Journal of clinical endocrinology and metabolism.
[13] P. Beck‐Peccoz,et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. , 2004, The Journal of clinical endocrinology and metabolism.
[14] W. Blum,et al. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. , 2004, The Journal of clinical endocrinology and metabolism.
[15] J. Björk,et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. , 2004, The Journal of clinical endocrinology and metabolism.
[16] A. Rostami-Hodjegan,et al. Weight‐related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency , 2004, Clinical endocrinology.
[17] A. Emser,et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. , 2004, The Journal of clinical endocrinology and metabolism.
[18] C. Roth,et al. Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. , 2003, The Journal of clinical endocrinology and metabolism.
[19] J. Fernández-Real,et al. Insulin resistance and chronic cardiovascular inflammatory syndrome. , 2003, Endocrine reviews.
[20] P. Ladenson,et al. Hypothyroidism and atherosclerosis. , 2003, The Journal of clinical endocrinology and metabolism.
[21] P. Ridker,et al. Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. , 2003, Clinical chemistry.
[22] R. Lustig. Autonomic Dysfunction of the β-Cell and the Pathogenesis of Obesity , 2003, Reviews in Endocrine and Metabolic Disorders.
[23] F. Orio,et al. The cardiovascular risk of GH-deficient adolescents. , 2002, The Journal of clinical endocrinology and metabolism.
[24] D. Cucinotta,et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. , 2001, European journal of endocrinology.
[25] K. Wheatley,et al. Association between premature mortality and hypopituitarism , 2001, The Lancet.
[26] R. Ross,et al. Estimation of skeletal muscle mass by bioelectrical impedance analysis. , 2000, Journal of applied physiology.
[27] B. Bengtsson,et al. Discontinuation of Growth Hormone (GH) Treatment: Metabolic Effects in GH-Deficient and GH-Sufficient Adolescent Patients Compared with Control Subjects* , 1999 .
[28] K. Sherif. Benefits and risks of oral contraceptives. , 1999, American journal of obstetrics and gynecology.
[29] P. Malmström,et al. Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. , 1998, The Journal of clinical endocrinology and metabolism.
[30] J. Bruner,et al. The descriptive epidemiology of craniopharyngioma. , 1998, Neurosurgical focus.
[31] R. Hayward,et al. Growth and endocrine sequelae of craniopharyngioma. , 1996, Archives of disease in childhood.
[32] R G Shulman,et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. , 1990, The New England journal of medicine.
[33] G. Bray,et al. Hypothalamic obesity , 1981, Diabetologia.
[34] T F Gallagher,et al. MANIFESTATIONS OF HYPOTHALAMIC OBESITY IN MAN: A COMPREHENSIVE INVESTIGATION OF EIGHT PATIENTS AND A EEVIEW OF THE LITERATURE , 1975, Medicine.
[35] N. Rifai,et al. C-reactive protein: a nontraditional serum marker of cardiovascular risk. , 2007, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[36] W. Arlt. Androgen therapy in women. , 2006, European journal of endocrinology.
[37] C. Cowell,et al. Features of the metabolic syndrome after childhood craniopharyngioma. , 2004, The Journal of clinical endocrinology and metabolism.
[38] F. Hanefeld,et al. Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite. , 1998, European journal of endocrinology.
[39] L. Wilhelmsen,et al. Physical activity, physical fitness and risk of myocardial infarction. , 1976, Advances in cardiology.